MUC1 and respiratory system disorder: These results demonstrated that serum KL-6 levels could be useful as a predictive biomarker for differentiating between severe TR-ILD and non-severe TR-ILD or non-ILD respiratory disease and for assessing the severity of TR-ILD in patients with lung cancer under treatment.